Roche Shares Under Pressure Following Clinical Trial Setback
Roche shares drop after giredestrant fails Phase III breast cancer trial. Analysts diverge on outlook as company pivots…
Roche’s Dividend Milestone Overshadowed by Clinical Trial Setback
Roche’s 39th consecutive dividend increase contrasts with a Phase III trial failure for giredestrant, pressuring shares and clouding…
Asian Investment and Clinical Trial Scrutiny
Roches, Strategic
05.03.2026 – 05:37:28 | boerse-global.de
Roche reports mixed Phase III results for…
Still no scare for Ohtuvayre: Roche IL-33 COPD data mixed
The fate of IL-33-targeting astegolimab will be determined by talks with regulators, after Roche AG’s Genentech unit rolled…
Swiss Rockets acquires Complete Genomics
Basel-based biotech group Swiss Rockets has acquired U.S. life sciences company Complete Genomics. The acquisition will strengthen Swiss…
Alps Group Inc Publishes Clinical Safety, Tolerability and Effectiveness Data Supporting Advancement of Its Autologous NK Cell Pipeline Using an In-House Developed Culture Protocol
KUALA LUMPUR, Malaysia, Feb. 23, 2026 (GLOBE NEWSWIRE) — Alps Group Inc (the “Company” or “Alps Group”), the…
MASH dash speeds up as Roche acquires 89bio for up to $3.5B
The dash for MASH is gaining momentum, with Roche AG acquiring 89bio Inc. and its phase III FGF21…
CERAN wrap: Roche phase III BC win seals thesis, boosts Olema
Roche AG’s Genentech unit landed another clinical victory with giredestrant that provided a major stock boost for competitor…